

sanofi-aventis Pakistan limited

**CONDENSED INTERIM
FINANCIAL STATEMENTS**
FOR THE HALF YEAR ENDED
30 JUNE, 2013

(UN-AUDITED)



SANOFI



Contents

2	Company Information
3	Directors' Report to the Shareholders
4	Auditors' Report to the Members
5	Condensed Interim Balance Sheet
6	Condensed Interim Profit & Loss Account
6	Condensed Interim Statement of Comprehensive Income
7	Condensed Interim Cash Flow Statement
8	Condensed Interim Statement of Changes in Equity
9	Notes to the Condensed Interim Financial Statements



Company Information

Board of Directors

Syed Babar Ali	Chairman
Tariq Wajid	Chief Executive
Arshad Ali Gohar	
Syed Hyder Ali	(Alternate Laila Khan)
Shailesh Ayyangar	(Alternate Shakeel Mapara)
Francois Jean Louis Briens	(Alternate Syed Muhammad Ali Hasani)
Jean-Marc Georges	
Mohammad Ibadullah	
Amanullah Khan	

Company Secretary

Saad Usman

Board Audit Committee

Syed Hyder Ali	(Chairman) Non-Executive Director
Francois Jean Louis Briens	Non-Executive Director
Amanullah Khan	Executive Director
Yasser Pirmuhammad	(Secretary) Associate Director Audit & Compliance

Share Transfer Committee

Tariq Wajid	General Manager and Chief Executive
Mohammad Ibadullah	Director Finance and Administration

Management Committee

Tariq Wajid	Mohammad Ibadullah
Syed Muhammad Ali Hasani	Amanullah Khan
Shakeel Mapara	Shujauddin Shaikh
Zubair Rizvi	Masaud Ahmed
Munawar Uqaili	Aamer Waheed
Laila Khan	Masood A.Khan
Harris Mohammed Sheikh	Yasser Pirmuhammad

Auditors

Ernst & Young Ford Rhodes Sidat Hyder
Chartered Accountants

Legal Advisors

Abid Hameed Puri
Bilal Law Associates
Fazle Ghani Advocates
Ghani Law Associates
Haidermota & Co.
Khan & Hafiz Associates
Saadat Yar Khan & Co

Bankers

Bank of Tokyo-Mitsubishi UFJ, Limited
Barclays Bank PLC
Citibank, N.A.
Deutsche Bank AG
Habib Bank Limited
HSBC Bank Middle East Limited
MCB Bank Limited.
National Bank of Pakistan
Standard Chartered Bank

Registered Office

Plot 23, Sector 22,
Korangi Industrial Area,
Karachi - 74900

Postal Address

P.O. Box No. 4962,
Karachi - 74000

Registrars & Share Transfer Office

FAMCO Associates (Pvt.) Ltd.
8-F, Next to Hotel Faran,
Nursery Block-6, P.E.C.H.S.
Sharah-e-Faisal, Karachi - 74000.
Telephone Nos. +92 21 34380101-2
Fax No. +92 21 34380106
URL: www.famco.com.pk

URL

www.sanofi.com.pk
www.sanofidiabetes.com.pk



Directors' Report to the Shareholders

The Board of Directors of sanofi-aventis Pakistan Limited is pleased to present the un-audited interim condensed financial statements of your company, for the half year ended June 30, 2013. These financial statements have been prepared in accordance with the requirements of the International Accounting Standards (IAS) 34 - "Interim Financial Reporting" and the provisions of and the directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provision of directives issued under the Companies Ordinance, 1984 have been followed.

The Company's net sales amounted to Rs.2,552 million and Rs.4,435 million for the quarter and half year ended June 30, 2013 respectively registering a growth of 9.95% and 4.55% over comparative prior periods. The sales growth, despite the challenging business environment, is the result of our strategy to become "A diversified healthcare company with patient centric approach".

The Company's pharmaceutical business net sales during the quarter and half year reached Rs.2,074 million and Rs.3,757 million respectively, recording a decrease of 1.6% and 4.5% over the comparative prior periods. During the period under review, the production of some products was temporarily discontinued due to expansion and refurbishment activities in production facility, resulting in some sales loss. Sales were also adversely affected during the period due to delay in award of import quotas from the Drug Regulatory Authority.

The vaccines business net sales for the quarter and half year reached Rs.253 million and Rs.351 million respectively recording a growth of 475% and 232% over the comparative prior period. The growth resulted due to sale of 13.125MD of polio vaccine during the period under report.

The consumer business net sales for the quarter and half year reached Rs.21 million and Rs.47 million respectively recording a growth of 65% and 111% over the comparative prior periods. The growth was backed by higher focus on distribution which provided the brand with a broader market as it has encapsulated both pharmacies and general stores, consequently, increasing the brand's presence and availability across the country.

Despite a challenging business environment, the Company continued on its path of exploring and materializing growth opportunities by focusing on bringing new products in the market that address patients' healthcare needs. During the half year, the Company launched three new products (namely Montelukast® in March 2013, Gastrolyte® in May 2013 and Sefrafilm® in May 2013) and one line extension (Gardan Suspension® in January 2013).

The Company pursued to increase its foothold in the export of pharmaceutical medicines in Afghanistan market as witnessed by the stellar growth in sales achieved during the half year. The Company recorded export sales of Rs.204 million and Rs.280 million for the quarter & half year, registering an increase of 30% and 57% respectively over comparative prior periods.

Gross margin as a percentage of net sales declined to 26.8% and 26.5% for the quarter and half year ended respectively from 27.1% and 28.1% during the comparative prior periods. The decline in margin is primarily attributable to the depreciation of Pak Rupee, vs. the USDollar and the Euro, increased depreciation expense, higher fuel & power costs due to excessive power failures as well as continued high inflation recording increase in all cost categories. These negative elements have been partly offset by the cost cutting measures taken by the management during the period.

Distribution and marketing expenses have decreased by 4.5% and 8%, on an overall basis, for the quarter and half year respectively over the comparative prior periods mainly due to lower spending on advertising and promotional activities, reduced travelling and conveyance as well as handling, freight & transportation expenses. These cost reductions helped to partly offset the increase in commission expenses pertaining to Vaccines tender business and higher staff cost on account of inflation as well as increase in headcount.

Administrative expenses decreased by 7.9% and 0.9% for the quarter and half year ended respectively over the corresponding periods last year mainly due to decrease in property taxes as well as security and maintenance costs due to disposal of Wah Site and reduction in travelling. This was offset by marginal increase recorded in other cost categories.

Other operating cost for the period mainly includes exchange losses amounting to Rs.40.06 million (2012: Rs.35.06 million) and statutory charges (i.e. Workers' Profits Participation Fund, Workers' Welfare Fund and Central Research Fund), which are all related to profit. The Company's financing cost during the half-year has increased by 40.8% during the period under report over comparative prior period, consequent to higher borrowing levels since the beginning of the current year.

Profit before and after taxes for the half-year has increased by Rs.18.45 million (11.8%) and Rs.30.86 million (47%) respectively over the comparative prior period because of the reasons explained above.

The Company devotes utmost importance to cash flow management and regularly monitors its day to day working capital and other financing requirements. During the half year the Company spent Rs. 251 million on account of capital expenditure and Rs.120 million on account of dividends. Subsequent to the half year end, the Company obtained a long term loan in order to finance its capital expenditure for the remainder of the year.

Notwithstanding unforeseen events, we expect the sales growth of the pharmaceutical business in the remaining quarters of 2013 to be in line with the industry trend. However, due to an adverse impact of Pak Rupee depreciation and an upsurge in inflation level, overall profitability is an area of concern for the Pharmaceutical Industry which can be mitigated through across the board price increase.

On behalf of the Board of Directors, we would like to acknowledge the hard work put in by all the employees of the Company.

By order of the Board

Syed Babar Ali
Chairman

Tariq Wajid
Chief Executive



Auditors' Report to the Members on Review of Interim Financial Information

Introduction

We have reviewed the accompanying condensed interim balance sheet of sanofi-aventis Pakistan Limited as at 30 June 2013 and the related condensed interim profit and loss account, condensed interim statement of comprehensive income, condensed interim statement of cash flows and condensed interim statement of changes in equity, together with the notes forming part thereof (herein after referred to as "interim financial information"), for the half year then ended. Management is responsible for the preparation and presentation of this interim financial information in accordance with approved accounting standards as applicable in Pakistan for interim financial reporting. Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagement 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with approved accounting standards as applicable in Pakistan for interim financial reporting.

Chartered Accountants

Audit Engagement Partner: Riaz A Rehman Chamdia

Ernst & Young Feroz Khan Noon & Co. Chartered Accountants

Karachi: August 22, 2013.



Condensed Interim Balance Sheet

As at June 30, 2013

	Note	June 30, 2013Rupees in `000..... (Un-audited)	December 31, 2012Rupees in `000..... (Audited)
ASSETS			
NON-CURRENT ASSETS			
Fixed assets			
Property, plant and equipment	4	1,757,718	1,628,173
Intangible asset		-	38
		<u>1,757,718</u>	<u>1,628,211</u>
Long-term loans		7,787	7,976
Long-term deposits		5,029	5,029
CURRENT ASSETS			
Stores and spares		50,911	48,102
Stock-in-trade		2,134,468	1,972,178
Trade debts		1,130,796	942,657
Short-term loans and advances		57,940	28,573
Trade deposits and short-term prepayments		103,691	61,652
Other receivables		29,906	36,600
Taxation - payment less provision		747,989	719,785
Cash and bank balances		16,495	4,944
		<u>4,272,196</u>	<u>3,814,491</u>
TOTAL ASSETS		<u>6,042,730</u>	<u>5,455,707</u>
EQUITY AND LIABILITIES			
SHARE CAPITAL AND RESERVES			
Share capital			
Authorized			
10,000,000 Ordinary shares of Rs. 10 each		<u>100,000</u>	<u>100,000</u>
Issued, subscribed and paid-up		96,448	96,448
Reserves			
Capital reserves		138,197	129,267
Revenue reserves		1,765,142	1,789,666
		<u>1,903,339</u>	<u>1,918,933</u>
		<u>1,999,787</u>	<u>2,015,381</u>
NON-CURRENT LIABILITIES		<u>120,027</u>	<u>156,283</u>
Deferred taxation			
CURRENT LIABILITIES			
Trade and other payables		1,814,128	1,694,420
Short term loan		200,000	-
Accrued mark-up		51,865	43,730
Running finances utilized under mark-up arrangements - Secured		1,856,923	1,418,440
Current maturity of long-term financing		-	125,000
Current maturity of liability against asset subject to a finance lease		-	2,453
		<u>3,922,916</u>	<u>3,284,043</u>
		<u>4,042,943</u>	<u>3,440,326</u>
CONTINGENCIES AND COMMITMENTS	5		
TOTAL EQUITY AND LIABILITIES		<u>6,042,730</u>	<u>5,455,707</u>

The annexed notes 1 to 11 form an integral part of these condensed interim financial statements.

Syed Babar Ali
Chairman

Tariq Wajid
Chief Executive

Karachi: August 22, 2013.



Condensed Interim Profit and Loss Account

For six months ended June 30, 2013 (Un-audited)

	Six Months Ended		Quarter Ended	
	June 30, 2013	June 30, 2012	June 30, 2013	June 30, 2012
Rupees in `000.....			
NET SALES	4,435,348	4,242,343	2,552,468	2,321,381
Cost of sales	(3,259,841)	(3,051,263)	(1,868,424)	(1,691,684)
GORSS PROFIT	1,175,507	1,191,080	684,044	629,697
Distribution and marketing expenses	(741,506)	(805,777)	(402,344)	(420,778)
Administrative expenses	(112,433)	(113,253)	(58,105)	(63,127)
Other operating expenses	(63,502)	(57,580)	(57,019)	(11,498)
Other operating income	19,526	14,936	13,779	13,275
	(897,915)	(961,674)	(503,689)	(482,128)
OPERATING PROFIT	277,592	229,406	180,355	147,569
Finance Costs	(102,620)	(72,888)	(54,805)	(42,964)
PROFIT BEFORE TAXATION FOR THE PERIOD	174,972	156,518	125,550	104,605
Taxation - Current	(115,193)	(85,057)	(71,652)	(48,883)
- Deferred	36,257	(6,285)	24,448	(701)
	(78,936)	(91,342)	(47,204)	(49,584)
NET PROFIT FOR THE PERIOD	96,036	65,176	78,346	55,021
BASIC EARNINGS PER SHARE (Rs. per share)	9.96	6.76	8.12	5.70

The annexed notes 1 to 11 form an integral part of these condensed interim financial statements.

Syed Babar Ali
Chairman

Tariq Wajid
Chief Executive

Karachi: August 22, 2013.



Condensed Interim Statement of Comprehensive Income

For the six months ended June 30, 2013 (Un-audited)

	Six Months Ended		Quarter Ended	
	June 30, 2013	June 30, 2012	June 30, 2013	June 30, 2012
Rupees in `000.....			
Net profit for the period	96,036	65,176	78,346	55,021
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	96,036	65,176	78,346	55,021

The annexed notes 1 to 11 form an integral part of these condensed interim financial statements.

Syed Babar Ali
Chairman

Tariq Wajid
Chief Executive

Karachi: August 22, 2013.




Condensed Interim Cash Flow Statement

For the six months ended June 30, 2013 (Un-audited)

	Note	June 30, 2013	June 30, 2012
.....Rupees in `000.....			
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	7	122,766	609,547
Finance costs paid		(94,485)	(63,885)
Income tax paid		(143,396)	(204,434)
Retirement benefits paid		(22,625)	(10,590)
Long-term loans (net)		189	(145)
Long-term deposits (net)		-	(360)
Net Cash (used in) generated from operating activities		<u>(137,551)</u>	<u>330,133</u>
CASH FLOWS FROM INVESTING ACTIVITIES			
Capital expenditure		(250,976)	(79,159)
Sale proceeds from disposal of operating fixed assets		8,822	3,832
Net cash used in investing activities		<u>(242,154)</u>	<u>(75,327)</u>
CASH FLOWS FROM FINANCING ACTIVITIES			
Repayment of liability against asset subject to finance lease		(2,453)	(1,268)
Repayment of long-term financing		(125,000)	(50,000)
Short term loan obtained		200,000	-
Dividends paid		(119,774)	(91,039)
Net cash used in financing activities		<u>(47,227)</u>	<u>(142,307)</u>
NET (DECREASE) / INCREASE IN CASH AND CASH EQUIVALENTS		<u>(426,932)</u>	<u>112,499</u>
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD		(1,413,496)	(912,630)
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	8	<u>(1,840,428)</u>	<u>(800,131)</u>

The annexed notes 1 to 11 form an integral part of these condensed interim financial statements.


Syed Babar Ali
Chairman


Tariq Wajid
Chief Executive



**Condensed Interim Statement of
Changes in Equity**
For the six months ended June 30, 2013 (Un-audited)

	Capital Reserves				Revenue Reserves		Total
	Issued, subscribed and paid-up share capital	Long term liabilities forgone	Difference of share capital under scheme of arrangement for amalgamation	Other	General reserve	Unappropri- ated profit	
	Rupees in '000.						
Balance as at January 1, 2012	96,448	5,935	18,000	78,808	1,185,538	216,606	1,601,335
Employee benefits cost under IFRS 2 "Share based payment"	-	-	-	14,759	-	-	14,759
Final Dividend @ Rs. 10/- per ordinary share for the year ended December 31, 2011	-	-	-	-	-	(96,448)	(96,448)
Transfer to general reserve	-	-	-	-	100,000	(100,000)	-
Net profit for the period	-	-	-	-	-	65,176	65,176
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	65,176	65,176
Balance as at June 30, 2012	96,448	5,935	18,000	93,567	1,285,538	85,334	1,584,822
Balance as at January 1, 2013	96,448	5,935	18,000	105,332	1,285,538	504,128	2,015,381
Employee benefit cost under IFRS 2 "Share based Payment"	-	-	-	8,930	-	-	8,930
Final dividend @ Rs. 12.5/- per ordinary share for the year ended December 31, 2012	-	-	-	-	-	(120,560)	(120,560)
Transfer to general reserve	-	-	-	-	250,000	(250,000)	-
Net profit for the period	-	-	-	-	-	96,036	96,036
Other comprehensive income / (loss) for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	96,036	96,036
Balance as at June 30, 2013	96,448	5,935	18,000	114,262	1,535,538	229,604	1,999,787

The annexed notes 1 to 11 form an integral part of these condensed interim financial statements.

Syed Babar Ali
Chairman

Tariq Wajid
Chief Executive



Notes to the Condensed Interim Financial Statements

For the six months ended June 30, 2013 (Un-audited)

1. THE COMPANY AND ITS OPERATIONS

The Company was incorporated in Pakistan in 1967 under the Companies Act, VII of 1913, as a Public Limited Company. The shares of the Company are listed on Karachi, Lahore and Islamabad Stock Exchanges. It is currently engaged in the manufacturing and selling of pharmaceutical and consumer products.

The registered office of the Company is located at Plot 23, Sector 22, Korangi Industrial Area, Karachi.

2. BASIS OF PREPARATION

- 2.1 These interim condensed financial statements of the Company for the six months ended June 30, 2013 have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 - "Interim Financial Reporting" and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of and directives issued under the Companies Ordinance, 1984 have been followed. These are required to be presented to the shareholders under Section 245 of the Companies Ordinance, 1984.
- 2.2 These condensed interim financial statements are unaudited and do not include all the information and disclosures as required in the annual financial statements and should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2012.
- 2.3 These Condensed interim financial statements are un-audited but subject to limited scope review by the auditors.

3. SIGNIFICANT ACCOUNTING POLICIES

- 3.1 The accounting policies and the methods of computation adopted in the preparation of these condensed interim financial statements are the same as those applied in the preparation of the financial statements for the year ended December 31, 2012 except other than those disclosed below:

New, amended and revised standards and interpretations

The Company has adopted the following revised standards, amendments, and interpretations of IFRSs which became effective for the current period:

- IAS 1 - Presentation of Financial Statements - Presentation of items of Other Comprehensive Income (Amendment)
- IAS 19 - Employee Benefits (Revised)
- IFRS 7 - Financial Instruments: Disclosures - (Amendment)
- Amendments enhancing disclosures about offsetting of financial assets and financial liabilities
- IFRIC 20 - Stripping Costs in the Production Phase of a Surface Mine

The adoption of the above revision and amendments of the standards did not have any effect on the financial statements, other than the amendments to IAS 19 'Employee Benefits' as described in note 3.2.

Further, certain new standards have been issued by IASB which are effective for accounting periods beginning on or after January 01, 2013 but are yet to be notified by the SECP for the purpose of applicability in Pakistan.

3.2 CHANGE IN ACCOUNTING POLICY

Amendments to IAS 19 range from fundamental changes to simple clarification and rewording. The significant changes to IAS 19 include the following:

- For defined benefit plans, the ability to defer recognition of actuarial gains and losses (i.e. the corridor approach) has been removed. As revised, actuarial gains and losses are recognized in other comprehensive income when they occur.
- Unvested past service costs can no longer be deferred and recognized over the future vesting period. Instead, all past service costs will be recognized at the earlier of when the amendment / curtailment occurs or when the entity recognizes related restructuring or termination costs.



Notes to the Condensed Interim Financial Statements For the six months ended June 30, 2013 (Un-audited)

- Expected returns on plan assets will no longer be recognized in profit or loss. Expected returns are replaced by recording interest income in profit or loss, which is calculated using the discount rate used to measure the pension obligation.

According to the management, the aforesaid change in accounting policy due to the adoption of amendments in IAS - 19 will result in increase in staff pension cost of prior years amounting to Rs. 1.224 million net of deferred tax amounting to Rs. 0.661 million, which the management believes is immaterial. As a result, such prior year effect has not been accounted for retrospectively in these condensed interim financial statements as required under IAS 8 "Accounting Policies, Changes in Accounting Estimates and Error".

		June 30, 2013	December 31, 2012
NoteRupees in `000.....	(Un-audited)	(Audited)
4. PROPERTY, PLANT AND EQUIPMENT			
Operating fixed assets	4.1	1,469,739	1,371,570
Capital work-in-progress		<u>287,979</u>	<u>256,603</u>
		<u>1,757,718</u>	<u>1,628,173</u>

4.1 Operating fixed assets

Following were the additions and disposals of fixed assets during the current period:

	Additions	Disposals	
		Cost	Accumulated Depreciation
.....Rupees in `000.....Rupees in `000.....Rupees in `000.....Rupees in `000.....
Building	106,760	-	-
Plant and Machinery	56,861	-	-
Furniture and fixtures	1,691	-	-
Factory and office equipment	6,717	1,425	1,420
Motor vehicles - owned	<u>47,572</u>	<u>21,046</u>	<u>18,876</u>
	<u>219,601</u>	<u>22,471</u>	<u>20,296</u>

5. CONTINGENCIES AND COMMITMENTS

Contingencies

- 5.1 Claims not acknowledged as debt amounted to Rs.6.200 (December 31, 2012: Rs. 6.200) million at the end of the current period.
- 5.2 There is no change in the status of contingencies in respect of income tax assessments, as set out in note 20.1 (b) to the annual financial statements of the Company for the year ended December 31, 2012.

Commitments

- 5.3 Commitments in respect of capital expenditure contracted for amounted to Rs. 128.452 million (December 31, 2012: Rs. 134.368 million) as at June 30, 2013.
- 5.4 Post dated cheques aggregating to Rs. 20.392 million (December 31, 2012: Rs. 46.047 million) at the end of the current period have been given to Collector of Customs in respect of exemption of levies on import of machine accessories.



Notes to the Condensed Interim
Financial Statements
For the six months ended June 30, 2013 (Un-audited)

	June 30, 2013	December 31, 2012
Rupees in `000.....	
5.5 Outstanding letters of credit	<u>168,348</u>	<u>73,153</u>
5.6 Outstanding bank contracts	<u>350,208</u>	<u>264,041</u>

6. OTHER OPERATING EXPENSES

This includes net exchange loss of Rs. 40,057 million (June 30, 2012: Rs. 35,064 million).

	Note	Six months ended June 30, 2013	Six months ended June 30, 2012
	Rupees in `000.....	
7. CASH GENERATED FROM OPERATIONS			
Profit before taxation		174,972	156,518
Adjustment for non-cash changes and other items:			
Depreciation / amortization		119,295	133,366
Fixed asset written off		-	88
Gain on disposal of operating fixed assets		(6,647)	(727)
Expenses arising from equity settled share based payment plans		8,930	14,759
Retirement benefits		21,704	12,741
Finance costs		102,620	72,888
Working capital changes	7.1	<u>(298,108)</u>	<u>219,914</u>
		<u>122,766</u>	<u>609,547</u>

7.1 Working Capital Changes

(Increase) / decrease in current assets:

Stores and spares	(2,809)	372
Stock-in-trade	(162,290)	(91,593)
Trade debts	(188,139)	(192,906)
Short-term loans and advances	(29,367)	(14,315)
Trade deposits and short-term prepayments	(42,039)	9,623
Other receivables - net	(363)	76,016
	<u>(425,007)</u>	<u>(212,803)</u>

Increase in current liabilities:

Trade and other payables - net (excluding unclaimed dividend)	126,899	432,717
	<u>(298,108)</u>	<u>219,914</u>

8. CASH AND CASH EQUIVALENTS

Cash and cash equivalents comprise of the following items:

Cash at bank - current accounts	16,495	11,956
Running finance utilized under mark-up arrangements	<u>(1,856,923)</u>	<u>(812,087)</u>
	<u>(1,840,428)</u>	<u>(800,131)</u>



Notes to the Condensed Interim
Financial Statements
For the six months ended June 30, 2013 (Un-audited)

9. TRANSACTIONS WITH RELATED PARTIES

Related parties comprise of associated undertakings, employees' provident fund, employees' gratuity fund, employees' pension fund, directors and key management personnel of the Company. The Company in the normal course of business carries out transactions with various related parties.

There are no transactions with key management personnel other than under the terms of employment.

Details of transactions with related parties during the period are as follows:

	June 30, 2013				June 30, 2012					
	Group companies	Related parties by virtue of common directorship	Retirement benefits plans	Key management personnel	Total	Group Companies	Related Parties by virtue of Common Directorship	Retirement benefits plans	Key management personnel	Total
	Rupees in '000									
i) Net Sales	25,195	-	-	-	25,195	24,508	-	-	-	24,508
ii) Purchase of goods	1,674,603	-	-	-	1,674,603	1,417,510	110	-	-	1,417,620
iii) Purchase of services	-	9,226	-	-	9,226	-	6,105	-	-	6,105
iv) Recovery of services charges and other expenses	-	-	-	-	-	-	4,061	-	-	4,061
v) License fee of land received	-	-	-	-	-	-	3,715	-	-	3,715
vi) Contribution paid/(receipt)										
- Provident Fund	-	-	16,658	-	16,658	-	-	13,904	-	13,904
- Gratuity Fund	-	-	3,918	-	3,918	-	-	40,107	-	40,107
- Pension Fund	-	-	18,707	-	18,707	-	-	(29,516)	-	(29,516)
vii) Remuneration of key - Management personnel	-	-	-	66,787	66,787	-	-	-	66,339	66,339

Further, the impact of benefits available to the Chief Executive and other employees recognized by the Company in the expenses during the period on account of share-based payment plans aggregated to Rs. 1,877 (2012: Rs.1,994) million and Rs. 7,053 (2012: Rs. 12,765) million, respectively.


10. DATE OF AUTHORISATION FOR ISSUE

These interim condensed financial statements were authorized for issue on August 22, 2013 by the Board of Directors of the Company.

11. GENERAL

11.1 The figures of the condensed interim profit and loss account and condensed interim statement of comprehensive income for the quarters ended June 30, 2013 and June 30, 2012 have not been subject to a limited scope review, as the scope of the review covered only cumulative figures for the six months ended June 30, 2013 and June 30, 2012.

11.2 Figures presented in these condensed interim financial statements have been rounded off to the nearest thousand rupees, unless otherwise stated.


Syed Babar Ali
Chairman


Tariq Wajid
Chief Executive